Blog

Reviews: 1. The Emperor of All Maladies: A biography of cancer, Siddhartha Mukherjee

From this January onward, the Hive writing team produces a monthly review on a key text. First in the series is the 2011 Pulitzer non-fiction winner – a vivid biography of humanity’s  greatest mortal dread.

At the conclusion to his extraordinary history of cancer, Siddhartha Mukherjee, an Indian-born, US-based cancer specialist, posits that ‘as the fraction of those affected by cancer creeps inexorably in some nations from one in four to one in three to one in two, cancer will, indeed, be the new normal – an inevitability. The question will not be if we will encounter this immortal illness, but when.’

That Mukherjee’s book is so compelling isn’t due solely to the drama of the story he tells, but because he is alive to the efficacy of art as well as science. ‘Normal cells are identically normal,’ he writes, ‘malignant cells become unhappily malignant in unique ways.’ His repurposing of Anna Karenina’s opening line is more than a rhetorical flourish: it’s indicative of the intelligent and illustrative way he approaches his material. Like all well-executed ideas, the question it raises is “Why hasn’t anyone done this before?”

The Emperor of All Maladies follows cancer from the palaces of ancient Persia to the R&D campuses of modern pharmaceutical companies. The majority of the story, however, takes place in the mid-to-late 20th century, when increased life expectancy in the western world saw the prevalence of cancer skyrocket (in third world countries cancer doesn’t even make the top 10 causes of death).

Mukherjee’s story centres on two figures who defined the post-war struggle against cancer. Sidney Farber was a paediatric pathologist who became the father of chemotherapy. Mary Lasker was a wealthy socialite and fearsome lobbyist who believed that if enough money was aimed at it, cancer could be vanquished. In 1971, after nearly 20 years of their campaigning, President Nixon declared the ‘War on Cancer’: legislation that devoted millions of dollars in federal funds to finding a cure.

Farber and Lasker’s achievement was of mixed worth. ‘Cancer,’ Mukherjee writes, ‘a shape-shifting disease of colossal diversity, was recast as a single, monolithic entity’. Scientists competed to find cures, theories of prevention were all but non-existent, and misguided treatments such as megadose chemotherapy did more harm than good.

Mukherjee’s recreation of the ambitions, disappointments and, occasionally, triumphs at each stage of the fight against cancer is one of his book’s greatest achievements. He successfully places the reader in whichever era, lab or ward he describes. He also renders cancer itself in a way that’s both horrifying and gripping. Of leukaemia he writes, ‘Its pace, its acuity, its breathtaking, inexorable arc of growth forces rapid, often drastic decisions; it is terrifying to experience, terrifying to observe, and terrifying to treat.’

The book’s final section is its most optimistic and most complex. Harold Varmus and J. Michael Bishop won the Nobel Prize in 1989 for proving the link between cancer and genes, which led to the subsequent identification of many oncogenes (genes with cancer-causing potential). ‘Having wandered in the darkness for decades,’ writes Mukherjee, ‘scientists had finally reached a clearing in their understanding of cancer. Medicine’s task was to continue that journey toward a new therapeutic attack.’ This came with development of drugs such as Herceptin, which targets an oncogene in a particular type of breast cancer.

But Mukherjee is too knowledgeable about cancer to be swept up in an optimism that has, time and again, proved false. Other gene-targeted therapies like Herceptin and Glivec may emerge over time, but that’s a forecast quite different to the ‘cure for cancer’ that has been dreamed of for so long. ‘This War on Cancer,’ he cautions, ‘may best be “won” by redefining victory.’

Mukherjee says the idea for his book was hatched when a patient asked him the simple question, ‘“What is it, exactly, that I am battling?”’ His answer, all 500 pages of it, is fascinating, depressing and exhilarating, and his writing on lung cancer is so affecting that, after 24 years of smoking, I haven’t had a cigarette since finishing the book six weeks ago.

Have you read this book? We’d love to have your comments.


There’s no i in experience design

Monday kicked off my winter night class on Experience Design at Central St. Martins. Asymetric haircuts, country headwear, the diverse and arty greeted me for a 10 stretch of academia. I even took a pencil to sketch  with whilst looking into the mid distance.

Experience design is just that and far from just that. Dozens of man-years have been spent crafting a definition that still struggles with the difference between art and design, let alone the requirement we have to trap, cagoule and force down the edges of what it is to be experiential or to provide experience. The wooliness of the subject is refreshing and helping get my head out of the structured, problem/solution world that billable work often requires (especially on a Monday!).

From 5 senses, to 360 degree immersive sessions it’s clearly going to be an awesome 10 weeks.

My reading list is whizzing past Hegel, Marx, through terms as diverse as relational aesthetics and dystopian community. It’s been a while since I read something (Harvard biz review tends to pride itself on accessibility!) that had me rubbernecking to google this regularly. Blindingly good stuff, even this early session got me thinking like mad on a stack of plans/briefs/trickies I have in front of me.

In a world where ‘Brand is…’ is cumbersome and ‘brand does’ becomes more central to our planning model - experiential planning is pretty sexy for me. It channel planning with lipstick on, spinning on a table, air thick with perfume.

With HBR continuing to kick sand in the face of goods providers with yet another article on the worth of the experience economy. Joining the greying of the boundaries between sponsorship, co-branding, commissioned design, corporate installation etc. And Josephs Pine conforming that customer value has run away from all the  commodities and goods, towards tailored services or authentic experiences. It it  the time to try and consider how we offer these experiences, planned, proactive and of course with an audience insight bang in the centre.

With crossed fingers, in a dark, endless cold room . I am hoping that experience design and the time spent with the talent at CSM contributes a component  to me working on a structured approach to behavioural change achieved along a considered, multichannel, richer journey.

In the meantime – a rather nice Nokia experience, corporate installation, co-branded event, light show or Son et lumière (your choice).


Chemo duck

I stumbled upon this gem of a programme whilst curating Patient Centricity news on Scoop it this morning.

Matt and I are heading up to Salford on the train, it’s pitch black, and dead depressing. This cheered me up somewhat and stirred a long gone memory.

I only just remember my sister being ill when I was about 6. A more distinct memory was her accompanying bear; Peri.  Peri pretty much was present all the way to health. Every now and then Peri is discovered still with his hospital wristband on and much smaller than I remember.  I now know that this little bear was named after a Heath Robinson looking yogurt pot, tube and bag gizmo that provided her with the peritoneal dialysis needed whilst her kidneys took a kicking,

This enterprising inspiring mum took her son’s similar requirement for a cancer companion to the next level. Just after his first birthday, Gabe’s mother, Lu Sipos, made the very first Chemo Duck for him. She thought he could use a companion to take to the hospital, one with whom he could share his journey back to health. Both Chemo Duck and Gabe finished treatment in November 2003 and have remained cancer free since.

Since then Lu along with a board of directors and a newly formed not for profit organisation have taken the chemo duck and made him fly. Chemo duck is now in production and the team are striving to give away 10,000 of these donated friends by Gabe’s 10 year birthday.

More than a companion chemo duck has become a vital part of ‘medical play’, a concept that allows children to communicate with parents and healthcare professionals, offering a window into their world midst the turmoil of cancer. Chemo duck is used time and time again as a powerful therapeutic and teaching tool used in medical facilities to familiarize children with cancer protocol and procedures.

Pretty cool eh?


Think like a patient

Around 2,000 teenagers and young adults in the UK are diagnosed with cancer every year. These vulnerable patients often feel isolated, bitter, confused and afraid as they struggle to come to terms with and overcome a life-threatening disease.

In recognition of the difficulties young cancer patients face, eyeforpharma are hosting their first annual Mobile Health Competition. Applicants must submit an idea for a phone application that will help teenage cancer patients manage their condition and make their lives easier. To help pick the winning idea eyeforpharma have created their very own super panel, comprised of teenage cancer survivors and charitable bodies.

The competition is open to anyone working for a pharmaceutical company, advertising agency, healthcare organisation, as well as patients themselves. The winner will have the opportunity to develop their application and see it launched. They will also win $5,000, which they can donate to a cancer charity of their choice.

The Teenager Cancer Trust, PatientsLikeMe, LIVESTRONG Young Adult Alliance, and a host of other charitable, patient, and mobile specialist companies have partnered with eyeforpharma for the competition.

Here at Hive we welcome any initiatives aimed at improving patient care and engagement, so we urge you to get involved and spread the word.

The closing date for entries is January 3rd 2012. 

http://www.eyeforpharma.com/mobilehealth/


Browse the archives: